Complex therapy of patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus in combination with seborrheic dermatitis
DOI:
https://doi.org/10.32782/2415-8127.2023.68.29Keywords:
non-alcoholic fatty liver disease, type 2 diabetes mellitus, seborrheic dermatitis, ursodeoxycholic acid, amino acid complexAbstract
Introduction. Non-alcoholic fatty liver disease (NAFLD) is a chronic disease based on increased lipid accumulation in hepatocytes. Today, the common pathogenetic mechanisms for NAFLD and metabolic syndrome have been proven, and their association with type 2 diabetes mellitus (DM) and other diseases is becoming evident. The aim of the study. To investigate the effectiveness of complex therapy using ursodeoxycholic acid (UDCA) and amino acid complex (AAC) in patients with NAFLD and type 2 diabetes mellitus in combination with seborrheic dermatitis (SD). Materials and methods. 78 patients with NAFLD and T2DM and SD were examined. Patients were divided into two groups: 1 group of examined patients with NAFLD and T2DM and SD was prescribed UDCA at a rate of 15 mg / kg body weight; in 2 group patients prescribed UDCA and AAC. Treatment was continued for 2 month. Results of the study. Complex therapy with the use of UDCA in combination with ACC proved to be more effective on the indicators of liver function. Therapy aimed at normalizing the indicators of the functional state of the liver contributed to a decrease in the severity of clinical symptoms of seborrheic dermatitis. A significant decrease in the number of patients with severe seborrheic dermatitis was found mainly in group II. Also, in patients taking UDCA and ACC, a decrease in scores from 42.1±1.8 to 28.7±2.0 (p<0.001) was found. These changes were accompanied by an increase in the number of patients with mild diabetes mellitus – by 32.5%, respectively (p<0.001). Conclusions. Complex therapy with the use of UDCA and ACC is an effective method for correcting the functional state of the liver, lipid metabolism in patients with NAFLD and type 2 diabetes mellitus in combination with DM. Normalization of liver function (reduction of cytolytic and cholestatic syndromes) in patients with NAFLD and type 2 diabetes mellitus helps to reduce the severity of clinical symptoms of DM in these patients.
References
Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, et al. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. Diabet Med. 2018 Mar;35(3):368-375. doi: 10.1111/dme.13565. Epub 2018 Jan 10. PMID: 29247558.
Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021 Jun 5; 397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3. Epub 2021 Apr 21. PMID: 33894145.
Lee CH, Lui DT, Lam KS. Non-alcoholic fatty liver disease and type 2 diabetes: An update. J Diabetes Investig. 2022 Jun;13(6):930-940. doi: 10.1111/jdi.13756. Epub 2022 Feb 14. PMID: 35080136; PMCID: PMC9153839.
Liu N, Wang G, Liu C, Liu J, Huang S, et al. Non-alcoholic fatty liver disease and complications in type 1 and type 2 diabetes: A Mendelian randomization study. Diabetes Obes Metab. 2023 Feb;25(2):365-376. doi: 10.1111/dom.14877. Epub 2022 Nov 2. PMID: 36181433.
Mocciaro G, Allison M, Jenkins B, Azzu V, Huang-Doran I, Herrera-Marcos LV, et al. Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL). Mol Metab. 2023 Jul; 73:101728. doi: 10.1016/j.molmet.2023.101728. Epub 2023 Apr 19. PMID: 37084865; PMCID: PMC10176260.
Akbaş A, Kılınç F, Şener S, Hayran Y. Investigation of the relationship between seborrheic dermatitis and metabolic syndrome parameters. J Cosmet Dermatol. 2022 Nov; 21(11):6079-6085. doi: 10.1111/jocd.15121. Epub 2022 Jun 7. PMID: 35621241.
Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, et al. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int J Mol Sci. 2021 Jan 4; 22(1):436. doi: 10.3390/ijms22010436. PMID: 33406763; PMCID: PMC7795122.
Ikeda K, Morizane S, Akagi T, Hiramatsu-Asano S, Tachibana K, Yahagi A, et al. Obesity and Dyslipidemia Synergistically Exacerbate Psoriatic Skin Inflammation. Int J Mol Sci. 2022 Apr 13;23(8):4312. doi: 10.3390/ijms23084312. PMID: 35457132; PMCID: PMC9032572.
Yak vyznachty optymalnu vahu: formula indeksu masy tila Available from: https://moz.gov.ua/article/health/jak-viznachtioptimalnu-vagu-formula-indeksu-masi-tila [In Ukrainian].
NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score Available from: https://www.mdcalc.com/calc/3081/nafld-nonalcoholic-fatty-liver-disease-fibrosis-score
Fibrosis-4 (FIB-4) Index for Liver Fibrosis Available from: https://www.mdcalc.com/calc/2200/fibrosis-4-fib-4-index-liverfibrosis 12. Zhang F, Li Y, Ren W, Li S. Establishment of clinical evaluation criteria for scalp seborrheic dermatitis. J Cosmet Dermatol. 2023 May 11. doi: 10.1111/jocd.15804. Epub ahead of print. PMID: 37170659.
Micali G, Lacarrubba F, Dall’Oglio F. A new proposed severity score for seborrheic dermatitis of the face: SEborrheic Dermatitis Area and Severity Index (SEDASI). J Am Acad Dermatol. 2017;76(6):AB18. doi: 10.1016/j.jaad.2017.04.088
Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018 Aug 14;24(30):3361-3373. doi: 10.3748/wjg.v24.i30.3361. PMID: 30122876; PMCID: PMC6092580.
Forzano I, Avvisato R, Varzideh F, Jankauskas SS, Cioppa A, Mone P, et al. L-Arginine in diabetes: clinical and preclinical evidence. Cardiovasc Diabetol. 2023 Apr 18;22(1):89. doi: 10.1186/s12933-023-01827-2. Erratum in: Cardiovasc Diabetol. 2023 May 18;22(1):117. PMID: 37072850; PMCID: PMC10114382.
Dobrijević D, Pastor K, Nastić N, Özogul F, Krulj J, et al. Betaine as a Functional Ingredient: Metabolism, Health-Promoting Attributes, Food Sources, Applications and Analysis Methods. Molecules. 2023 Jun 17;28(12):4824. doi: 10.3390/molecules28124824. PMID: 37375378; PMCID: PMC10302777.
Sanford JD, Franklin D, Grois GA, Jin A, Zhang Y. Carnitine o-octanoyltransferase is a p53 target that promotes oxidative metabolism and cell survival following nutrient starvation. J Biol Chem. 2023 Jul; 299(7):104908. doi: 10.1016/j.jbc.2023.104908. Epub 2023 Jun 10. PMID: 37307919; PMCID: PMC10339192.
